Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial entities : Aldeyra therapeutics, inc. save search
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
Published: 2024-01-04 (Crawled : 13:30) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: 0.9%
H: 1.18%
C: -1.18%
update therapeutics platform
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
Published: 2023-12-18 (Crawled : 23:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: 1.32%
H: 3.27%
C: -3.27%
adx-629 conference dermatitis trial therapeutics results
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Applied Digital Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLD
Published: 2023-09-09 (Crawled : 20:20) - prnewswire.com
APLS G | $49.59 1.79% 630K
|
Health Technology
| Email alert
Add to watchlist
APLD | $3.015 2.9% 4.4M
|
Manufacturing
| Email alert
Add to watchlist
ALDX | $3.895 -0.38% 360K
|
Health Technology
| Email alert
Add to watchlist
corporation deadline trial
ROSEN, NATIONAL TRIAL LAWYERS, Encourages KeyCorp Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - KEY
Published: 2023-08-25 (Crawled : 00:20) - prnewswire.com
KEY | $14.865 0.99% 12M
|
Finance
| Email alert
Add to watchlist
BTAI | News | $2.685 -9.6% 830K
|
Health Technology
| Email alert
Add to watchlist
ALDX | $3.895 -0.38% 360K
|
Health Technology
| Email alert
Add to watchlist
deadline trial
Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa
Published: 2023-06-29 (Crawled : 12:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: -0.91%
H: 3.92%
C: 3.13%
trial therapeutics
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa
Published: 2023-06-28 (Crawled : 22:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: -0.67%
H: 6.07%
C: 4.32%
adx-2191 conference trial therapeutics results
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough
Published: 2023-06-27 (Crawled : 12:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: 1.2%
H: 5.26%
C: -1.84%
trial therapeutics
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough
Published: 2023-06-26 (Crawled : 22:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: -0.98%
H: 10.16%
C: 6.68%
conference trial therapeutics results
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain
Published: 2023-05-23 (Crawled : 15:00) - prnewswire.com
NVSEF | News | $96.0 52K
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: -0.62%
NVS | News | $98.31 1.06% 1.6M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -1.22%
GKOS | $102.645 1.53% 260K
|
Health Technology
|
| O: -0.71%
H: 2.06%
C: -1.05%
BHC | $8.5 -0.35% 810K
|
Health Technology
|
| O: -2.27%
H: 4.24%
C: -2.21%
ALC | $79.68 -1.34% 500K
|
Health Technology
|
| O: -0.51%
H: 0.02%
C: -3.25%
ABBV | News | $168.055 -0.88% 1.8M
|
Health Technology
|
| O: -0.31%
H: 0.26%
C: -1.34%
SNY | News | $46.765 -1.94% 1.2M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
OCUL | News | $4.585 -8.3% 2.8M
|
Health Technology
|
| O: 4.45%
H: 7.65%
C: 2.21%
GRFS | $6.32 -2.47% 640K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -3.74%
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: 0.0%
H: 2.36%
C: 0.61%
pharma disease pipeline set eye trial
Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis
Published: 2023-04-13 (Crawled : 12:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: 0.9%
H: 8.2%
C: 2.58%
trial therapeutics
Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis
Published: 2023-04-06 (Crawled : 14:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: 0.0%
H: 2.26%
C: 1.64%
adx-629 dermatitis trial therapeutics phase 2
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough
Published: 2023-03-30 (Crawled : 18:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: 0.0%
H: 2.43%
C: 0.53%
adx-629 trial therapeutics phase 2
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: -1.79%
H: 5.34%
C: 3.78%
trial therapeutics phase 2
Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: 1.26%
H: 3.88%
C: -6.24%
reproxalap disease eye trial therapeutics positive results
Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
Published: 2023-02-23 (Crawled : 13:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: 0.58%
H: 5.3%
C: 5.3%
trials drug expected therapeutics
Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials
Published: 2023-02-16 (Crawled : 18:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: -1.09%
H: 8.6%
C: 6.62%
trials disease therapeutics phase 2
Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial
Published: 2022-12-13 (Crawled : 14:20) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: 3.05%
H: 0.0%
C: -1.09%
adx-629 alcohol trial phase 2
Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting
Published: 2022-10-26 (Crawled : 13:20) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: 0.0%
H: 8.0%
C: 7.81%
meeting therapeutics presentation
Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
Published: 2022-10-06 (Crawled : 12:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: 1.61%
H: 2.12%
C: -3.35%
adx-2191 trial therapeutics
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
Published: 2022-10-05 (Crawled : 23:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: -1.46%
H: 3.9%
C: 3.53%
adx-2191 conference trial therapeutics results
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3831 151.54% 190M
|
Consumer Services
CZOO | $11.04 121.24% 11M
|
LICN | $0.9107 62.63% 14M
|
BOF | $1.87 59.83% 100M
|
AMST | $3.18 59.0% 67M
|
Technology Services
SKIL 4 | $8.72 52.72% 410K
|
Information
MTC | $3.31 47.77% 7.7M
|
Technology Services
MULN | News | $3.915 43.41% 12M
|
Information
WIMI | $1.04 43.37% 17M
|
Technology Services
RILY | $29.755 36.99% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.